Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Silence Therapeutics Plc on Equity Fundraising

May 2, 2013

LONDON, 2 May, 2013 — Silence Therapeutics Plc, a leader in the discovery, development and delivery of novel RNA interference therapeutics for the treatment of serious diseases, has successfully raised £18.7 million of new funds. Covington & Burling advised Silence Therapeutics on the transaction.

The Company expects to use the net proceeds of the placing of £18.7 million to fund a Phase Ib/IIa programme of Atu027, its most advanced internal drug candidate for the treatment of solid tumours, as well as to develop its non-cancer projects and broaden its clinical expertise.

The London-based Covington team was led by corporate partner Natalie Walter with assistance from corporate associate Simon Williams.

Share this article: